Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)

Abstract The MITO-END3 trial compared carboplatin and paclitaxel (CP) with avelumab plus carboplatin and paclitaxel (CPA) as first-line treatment in endometrial cancer (EC) patients and demonstrated a significant interaction between avelumab response and mismatch repair status. To investigate progno...

Full description

Saved in:
Bibliographic Details
Main Authors: C. D’Alterio, G. Rea, M. Napolitano, E. Coppola, A. Spina, D. Russo, R. Azzaro, C. Mignogna, G. Scognamiglio, D. Califano, L. Arenare, C. Schettino, C. Pisano, S. C. Cecere, M. Di Napoli, A. Passarelli, F. Perrone, S. Pignata, S. Scala
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Endometrial cancer
Chemotherapy
Avelumab
Myeloid-derived suppressor cells
The Cancer Genome Atlas (TCGA)-based molecular classification
Online Access:https://doi.org/10.1007/s00262-025-04021-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04021-3

Similar Items